0.52  -0.001 (-0.19%)		09-18 16:00
Open: 0.5334 High: 0.5334 Volume: 112,836		Pre. Close: 0.521 Low: 0.5003 Market Cap: 8(M)

Short term
Mid term
Targets	6-month :	0.67	1-year :	0.73
Resists	First :	0.58	Second :	0.62
Pivot price	0.55
Supports	First :	0.5	Second :	0.41
MAs	MA(5) :	0.52	MA(20) :	0.56
	MA(100) :	0.75	MA(250) :	0.98
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	5.7	D(3) :	7.6
RSI	RSI(14): 38.8
52-week	High :	2.04	Low :	0.5

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ONVO ] has closed above bottom band by 21.1%. Bollinger Bands are 40.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.53 - 0.54	0.54 - 0.54
Low:	0.49 - 0.5	0.5 - 0.5
Close:	0.52 - 0.52	0.52 - 0.52

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

Thu, 19 Sep 2024
Organon makes dermatology play with $1.2bn Dermavant buyout - pharmaphorum

Thu, 19 Sep 2024
Organon to Acquire Roivant’s Dermatology Subsidiary for Up to $1.2B - Femtech Insider

Wed, 18 Sep 2024
Organon Moves Into Branded Dermatology With Dermavant Takeout - Scrip

Wed, 18 Sep 2024
Organon To Buy Psoriasis Treatment Biz For Up To $1.2B - Law360

Wed, 18 Sep 2024
Organon Gets More Skin in the Game by Acquiring Roivant’s Dermatology Subsidiary - MedCity News

Wed, 18 Sep 2024
Organon to acquire Dermavant in back-loaded deal - The Pharma Letter

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	15 (M)
Held by Insiders	1.518e+007 (%)
Held by Institutions	2 (%)
Shares Short	115 (K)
Shares Short P.Month	0 (K)

EPS	-1.399e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-8 %
Return on Assets (ttm)	682 %
Return on Equity (ttm)	-73.7 %
Qtrly Rev. Growth	73000 %
Gross Profit (p.s.)	-78.69
Sales Per Share	-248.73
EBITDA (p.s.)	0
Qtrly Earnings Growth	-1.4 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-12 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.01
Price to Cash Flow	0.68

Dividend	0
Forward Dividend	87140
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.